跳到正文
PharmOut GMP 专业解读·AI 评分69

PIC/S PE 009-18 于 2026 年 9 月 24 日生效,PharmOut 解读修订版附件 19 的样品要求

PIC/S PE 009-18 is now in force: What the revised Annex 19 means for GMP professionals

AI 导读

PIC/S 发布 PE 009-18 修订药品 GMP 指南,文件于 2026 年 9 月 24 日生效,实质性变化集中在附件 19 第 9 节。

正文 · 原文

A practical guide to the new reference and retention sample expectations for parallel imported, parallel distributed and parallel traded products

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has released PE 009-18, revising its Guide to Good Manufacturing Practice for Medicinal Products which entered into force on 24 September 2026. The substantive change is focused: Annex 19, Reference and Retention Samples, particularly Section 9 for parallel imported, parallel distributed and parallel traded products.

Key Takeaways

  • PIC/S PE 009-18 introduces targeted but important changes to Annex 19.
    The revised PIC/S GMP Guide came into force on 24 September 2026, with the main changes focused on Annex 19 Section 9. The update clarifies requirements for reference samples, retention samples, packaging-material retention, and the use of digital alternatives for parallel imported, distributed, and traded products.
  • Reference samples and retention samples are no longer treated as the same thing.
    IPE 009-18 clearly distinguishes between reference samples used for analytical testing and retention samples used for identification and packaging examination. For repackaged products, reference samples are no longer required, but a representative retention sample is required for every repackaging operation.
  • The greatest impact will be on parallel trade and repackaging operations.
    Organisations involved in parallel importation, parallel distribution, or parallel trade should assess whether Section 9 applies in their jurisdiction. Repackagers, importers, distributors, contract packaging organisations, batch-release functions, and quality units may all need to update procedures, records, agreements, and storage arrangements.
  • Digital retention samples are allowed only under strict conditions.
    Photographic or electronic records cannot be used as a convenient replacement for physical samples. A digital alternative requires documented justification, prior competent authority approval, and robust Annex 11-compliant data integrity controls to ensure records remain complete, secure, traceable, and retrievable throughout the retention period.
  • A documented GMP gap assessment should be the first compliance step.
    GMP professionals should begin by confirming applicability, then perform a clause-by-clause assessment against Annex 19 requirements. Organisations within scope should update sampling procedures, batch records, storage controls, technical agreements, training programs, and electronic systems as part of a controlled quality system change process.

Although the amendment is narrow, its operational effect can be significant for organisations that repackage products within the scope of local parallel trade legislation. The revision clarifies what physical packaging materials must be retained, separates reference samples from retention samples, defines the expected contents and retention period for finished-product samples, and introduces a tightly controlled photographic or digital alternative where physical retention is not reasonably possible.

For Good Manufacturing Practice (GMP) professionals, this is not simply a document-control update. It calls for a targeted applicability assessment, revised sampling and storage arrangements, clear ownership across supply and quality agreements, and appropriate data-integrity controls where electronic images are used.

What changed in PE 009-18?

A controlled textual comparison of PE 009-17 and PE 009-18 identified thirteen reportable changes: two in the Introduction and eleven in Annex 19. No differences were implemented in Part I or Part II. Within Annex 19, clause 6.1 contains a minor wording clarification, while the meaningful requirements are concentrated in Section 9.

Why the distinction between reference and retention samples matters

Annex 19 uses two related but different concepts.

  1. A reference sample supports analytical testing if future examination is required.
  2. A retention sample is a fully packaged unit retained primarily for identification and presentation-related examination.

PE 009-18 makes the distinction particularly clear for repackaged products: reference samples of the repackaged product are not required, but a representative retention sample is required for each repackaging operation.

This distinction should reduce ambiguity, but only if procedures and records use the terms consistently. GMP professionals may benefit from checking whether local procedures incorrectly treat all retained materials as “reference samples”, or use a single sampling instruction without distinguishing analytical purpose from visual and packaging examination. Definitions, sampling plans, labels, registers and destruction records should align.

PE 009-18: The difference between and reference and retention sample

Who is likely to be affected?

The direct impact falls on organisations conducting repackaging associated with parallel importation, parallel distribution or parallel trade where local legislation brings those activities within scope. Depending on the operating model, affected parties may include repackagers, importers, distributors, contract packaging organisations, batch-release functions, product owners and quality units responsible for technical or quality agreements.

Section 9 retains an important jurisdictional limitation: it applies only where national legislation addresses these activities. PIC/S has invited non-European Economic Area participating authorities and applicants to transpose the revised Annex 19 into their own GMP guides. Therefore, PIC/S publication does not by itself establish the legal implementation date in every jurisdiction. Australian manufacturers and sponsors should monitor the Therapeutic Goods Administration’s formal adoption position and applicable manufacturing principles rather than assuming automatic domestic effect.

The practical impact of PE 009-18 on GMP systems

Sampling procedures and batch records

Repackaging instructions should identify the materials and finished-product samples to take at each operation, who takes them, how they are identified, and how completion is documented. Batch packaging records should provide direct traceability to retained packaging components and to any physical or approved digital retention sample.

Storage capacity and retention periods

The revised requirements may change storage demand. Packaging-material samples are linked to the shelf-life of the repackaged finished product, while the finished-product retention sample is kept for at least one year after expiry. Organisations should assess available space, environmental controls, segregation, sample retrieval and secure destruction. The review should use actual product volumes and repackaging frequency rather than relying on a generic estimate.

Quality and technical agreements

Where activities are outsourced or split across sites, agreements should allocate responsibility for taking, transporting, storing, retrieving and destroying samples. They should also address investigation access, competent-authority requests, data ownership and business continuity. Clause 6.1 received only a wording clarification, but it remains sensible to confirm the interface between the sample-holding site and the site with overall responsibility for the batch.

Digital evidence and data integrity

The digital option should not be treated as a convenient default. PE 009-18 makes it conditional on a documented justification that physical retention is not reasonably possible and prior agreement with the competent authority. Where approved, the photographic or digital record must be sufficiently complete and high quality to permit full visual examination and investigations equivalent to those possible with a physical retention sample.

PE 009-18: Keeping physical retention samples

That expectation reaches beyond taking a few photographs. The record should capture relevant primary and secondary packaging data, including identifiers such as batch number and expiry date, show evidence of applied safety features, and enable identification of braille information where applicable. Electronic storage should follow Annex 11 principles so that integrity is maintained throughout the retention period. In practice, this points to controlled capture methods, attributable records, protected files, governed metadata, access controls, backup, retrieval testing and managed retention.

A proportionate compliance action plan

PE 009-18: A proportionate compliance action plan

1. Confirm applicability

Map products, markets and repackaging activities against local legislation. Document whether Section 9 applies and identify the responsible legal and manufacturing entities.

2. Perform a clause-by-clause gap assessment

Compare Annex 19 clauses 9.1 to 9.5.4 with procedures, batch records, sample registers, storage controls, agreements and electronic systems. Record objective evidence and owners for each gap.

3. Open change control

Manage the transition through the pharmaceutical quality system. Define scope, regulatory assessment, affected documents, training, system changes, validation needs and effectiveness checks.

4. Revise procedures and records

Update terminology, sample quantities, composition, labelling, traceability, retention periods, retrieval, investigation use and destruction. Ensure repackaging records prompt operators to capture the required evidence.

5. Reassess sample storage

Forecast physical storage using product shelf-life, batch or operation frequency and sample dimensions. Confirm environmental conditions, security, segregation and retrieval remain suitable.

6. Review outsourced responsibilities

Update quality or technical agreements where another party repackages, holds samples, maintains digital records or supports batch release and investigations.

7. Control any proposed digital alternative

Do not implement photographic or digital substitution without the required justification and prior competent-authority agreement. Define the complete image set, quality criteria, metadata, traceability and Annex 11 controls.

8. Train affected personnel

Focus training on the reference-versus-retention distinction, the per-operation requirement, packaging-material retention, digital evidence expectations and local applicability.

9. Verify effectiveness

Use a targeted self-inspection or batch-record review to confirm that samples are taken, recorded, stored and retrievable as intended. Track overdue actions through the quality system.

Common compliance traps to avoid

  • Assuming that the release of a PIC/S guide automatically changes legal requirements in every country.
  • Applying the new controls to all products without first determining whether Section 9 and local parallel trade legislation are relevant.
  • Keeping packaging examples but failing to link them to the specific repackaging operation or batch record.
  • Using “reference sample” and “retention sample” interchangeably in procedures and registers.
  • Treating photographs as an informal substitute for physical samples without justification and prior authority agreement.
  • Storing images on uncontrolled drives or collaboration spaces without defined integrity, access, backup and retention controls.
  • Updating the sampling procedure but overlooking batch records, agreements, storage qualification, training and destruction processes.

What should GMP professionals do now?

Starting with a focused applicability assessment will usually provide the most efficient route. Organisations outside parallel trade or repackaging may need only to document why the revised Section 9 does not affect their operations and continue monitoring local adoption. Organisations within scope should progress a controlled gap assessment and change plan, with early attention to sample-storage capacity and outsourced responsibilities.

Where a digital alternative may be necessary, engaging the competent authority should be treated as a prerequisite rather than a closing action. The justification and proposed evidence standard should be mature enough to show that the digital record will support examination and investigation equivalent to a physical retention sample.

Targeted Change, Tangible GMP Impact

PE 009-18 is a targeted revision, but targeted does not mean trivial. For affected repackaging operations, the revised Annex 19 establishes clearer expectations for packaging-material samples, finished-product retention samples and any exceptional use of photographic or digital evidence. The strongest response will combine jurisdictional awareness with practical quality-system execution: confirming applicability, controlling the change, updating records and agreements, protecting sample integrity, and verifying that evidence remains retrievable for inspection and investigation.

PharmOut can support organisations with applicability assessments, GMP gap analysis, pharmaceutical quality system updates, sampling and retention procedures, technical agreements, Annex 11 assessments and inspection readiness. Early, proportionate action may reduce storage, documentation and data-integrity surprises as national authorities transpose the revised standard.

PharmOut Training & Services

PharmOut can help organisations translate PE 009-18 into practical, proportionate controls. Our consultants can assess applicability, complete targeted GMP gap assessments, update sampling and retention procedures, review storage and technical agreements, strengthen Annex 11 data-integrity controls, train personnel and support inspection readiness – helping clients implement the revised Annex 19 requirements with confidence.

Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.

Frequently asked questions

Are reference samples of repackaged products required?

No. Revised clause 9.2 states that reference samples of the repackaged product are not required. However, this does not remove the separate requirement for a retention sample from each repackaging operation.

How long must a retention sample be kept?

A retention sample of the repackaged finished product should be retained for at least one year after its expiry date. Packaging materials used during repackaging should be retained for the product’s shelf-life.

Can photographs replace the physical retention sample?

Potentially, but only when physical retention is duly justified as not reasonably possible and the competent authority agrees in advance. The digital record must meet detailed completeness, quality, traceability and integrity expectations.

What electronic controls apply to digital samples?

Clause 9.5.4 points to Annex 11 principles. The electronic record should remain complete, legible, traceable, protected and retrievable throughout retention, with controls proportionate to its GMP significance.

What is the best first compliance action?

Begin by documenting applicability. Map repackaging and parallel trade activities, jurisdictions, products, sites and contracts. This prevents unnecessary system changes while ensuring genuinely affected operations receive a structured gap assessment.

来源:PharmOut GMP 专业解读 · pharmout.net